Patents by Inventor Stephane Demotz

Stephane Demotz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation of isolated agonist anti-EDAR monoclonal antibodies
    Patent number: 8741297
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: June 3, 2014
    Assignees: Edimer Pharmaceuticals, Inc., Universite de Lausanne
    Inventors: Pascal Schneider, Nathalie Dunkel, Stéphane Demotz
  • PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES
    Publication number: 20130273046
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Application
    Filed: March 8, 2013
    Publication date: October 17, 2013
    Applicants: UNIVERSITE DE LAUSANNE, EDIMER PHARMACEUTICALS, INC.
    Inventors: Pascal Schneider, Nathalie Dunkel, Stéphane Demotz
  • CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF
    Publication number: 20130274258
    Abstract: Compounds of general formula (I), wherein A, Y, R1 and R2 are defined herein are useful in the treatment or prevention of proliferative diseases including cancer or infectious or parasitic diseases.
    Type: Application
    Filed: November 3, 2011
    Publication date: October 17, 2013
    Applicant: PHILIP MORRIS PRODUCTS S.A.
    Inventors: Stephane Demotz, Gerhard Lang, Damian McHugh, Axel Teichert, Fernando Goffman, Paul M. Doyle, Paul M. Blaney, Raymond Fisher, Andrew Smith, Emma L. Blaney, Simon Foster
  • Preparation of isolated agonist anti-EDAR monoclonal antibodies
    Patent number: 8496937
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: July 30, 2013
    Assignees: Edimer Pharmaceuticals, Inc., Universite de Lausanne
    Inventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
  • PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES
    Publication number: 20120192296
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Application
    Filed: March 30, 2010
    Publication date: July 26, 2012
    Applicants: Universite de Lausanne, Edimer Biotech S.A.
    Inventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
  • Method to Reduce Hepatoxicity of Fas-Mediated Apoptosis-Inducing Agents
    Publication number: 20080003226
    Abstract: The invention concerns a method to prevent or reduce adverse effects on liver of a patient treated with a Fas-mediated apoptosis-inducing agent, the method comprising the administration of a product preventing TNF receptors-mediated apoptosis of the liver cells.
    Type: Application
    Filed: May 27, 2005
    Publication date: January 3, 2008
    Applicant: APOXIS SA
    Inventors: Marc Dupuis, Stephane Demotz, Rene Goedkoop
  • Synthetic chemokines labeled at selected positions
    Publication number: 20040138422
    Abstract: Labeled synthetic chemokine molecules are provided which are characterized by improved biological activity and methods for their production and use in detection of chemokine receptors.
    Type: Application
    Filed: September 23, 2003
    Publication date: July 15, 2004
    Inventors: Stephane Demotz, Corinne Moulon, Christophe Reymond, Mario Roggero, Andrew Strong, Jean Vizzavona, Pascal Cousin